Akili functions on the premise that advances in neuroscience research and consumer-facing technology are enabling a new way to sensitively measure neural function, and intervene in any measured deficits, wherever the patient may be. Akili's products address both quantitative measurement of and intensive intervention in cognitive functions in a variety of patient populations.
The science behind our proprietary technology platform was developed at the University of California, San Francisco by Dr. Adam Gazzaley, Founding Director of the UCSF Neuroscape and Akili's Chief Science Advisor. Dr. Gazzaley's research has led to a patent-pending new software-based method to measure and improve a key system of executive function known as interference processing™. We've deployed these mechanics from the ground up in a consumer video game interface that runs on mobile phones and tablets, and meets all requirements for rigorous clinical studies. The Project: EVO™platform is currently being tested in a variety of clinical studies in multiple patient populations around the globe, including ADHD, autism, depression, and traumatic brain injury.